|Traded as||NYSE: Q|
|Industry||Contract Research Organization
Pharmaceutical Service Consulting
|Headquarters||Durham, North Carolina, USA|
|Key people||Dennis Gillings, Executive Chairman
Tom Pike CEO
; Paula Brown Stafford, President Clinical
|Products||Support services for pharmaceutical, biotech and medical companies and individuals|
|Revenue||US$ Approximately $3.8 billion (2013)|
|Employees||~ 32,000 (2014)|
Quintiles Transnational (NYSE: Q), is a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 32,000 employees conducting business in approximately 100 countries.
Quintiles is the world’s largest contract research organization as ranked by reported service revenues, and is focused primarily on Phase II-IV clinical trials and associated laboratory and analytical services. Quintiles' Integrated Healthcare Services supports diverse functions, including contract pharmaceutical sales in many geographic markets, as well as a growing number of healthcare business services, such as outcome-based and payer/provider services.
- 1974: Dennis Gillings signs first contract to provide statistical and data management consulting for pharmaceutical clients.
- 1982: Quintiles, Inc., is incorporated in North Carolina.
- 1990: Quintiles Pacific Inc. and Quintiles Ireland Ltd. established
- 1991: Quintiles GMBH established in Germany; Quintiles Laboratories Ltd. established in Atlanta, Georgia
- 1996: Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO
- 1997: Quintiles goes public, completing successful secondary stock offering.
- 1998: Quintiles is the first company in industry to break the $1 billion mark, when it reported net revenues of $1.19 billion.
- 1999: Company joins the S&P 500 Index.
- 2003: Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
- 2009: Quintiles opens new corporate headquarters in Durham, North Carolina
- 2010: Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
- 2011: Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York
- 2013: Quintiles files for an IPO on 15 February in order to go public again 
- 2013: Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q 
- 2014: Quintiles named to the FORTUNE 500.
- "Money, Math and Medicine". Forbes Magazine. November 22, 2010. Retrieved April 14, 2011.
- "High-Flying Quintiles to Buy Innovex in $747.5 Million Deal". New York Times. October 8, 1996. Retrieved April 14, 2011.
- Wall Street Journal, May 9, 2013